December 26, 2022
Sanofi said on December 23 that Cablivi (caplacizumab) is now available in Japan for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). It is a drug featuring a new mechanism of action for aTTP. According to the company, aTTP is...read more